Stocks
Agios Pharmaceuticals, Inc.AGIO
NASDAQHealthcareBiotechnology$27.85+0.94%
Focused on developing therapies for rare genetic diseases and cancer, this biopharmaceutical company has attracted investor attention for its work in cellular metabolism. Its lead drug targets pyruvate kinase deficiency, a rare blood disorder, while its oncology pipeline includes investigational treatments for solid tumors. The company's valuation reflects both its commercialized products and potential in precision medicine.
Market Cap: $1.6B52W Range: $22.24 – $46.00
Congressional Interest in Agios Pharmaceuticals, Inc. (AGIO)
3 members of Congress have disclosed 7 trades in Agios Pharmaceuticals, Inc. (AGIO), a Healthcare company. The buy/sell breakdown shows 6 purchases versus 1 sale, indicating net buying interest from lawmakers. All data is sourced from STOCK Act periodic transaction reports filed with Congress.
Total Disclosures
7
Unique Politicians
3
Buys
6
Sells
1
Who in Congress Is Trading AGIO?
| Date | Politician | Type | Amount |
|---|---|---|---|
| 2026-03-03 | Gilbert Cisneros | buy | $1K – $15K |
| 2025-12-11 | Gilbert Cisneros | buy | $1K – $15K |